CN
AbOUT US


画板 3.jpg


We keep exploring and constantly perfecting our technology.

We are committed to developing the best active medical devices in China and bringing more advanced,

safer, more effective and more favourable treatments to patients in China and around the world.


  • 2022year
    Pulsed Field Ablation Therapeutic Apparatus was approved as the first domestically produced PFA product by China’s Innovative Medical Device Special Approval.
  • 2021year
    • Pulsed Field Ablation Therapeutic Apparatus obtained authorization of patent for an invention and started multicenter clinical trial nationwide.
    • Steep Pulse Therapeutic Apparatus obtained the first registration certificate for medical device(Class III) which is targeted at treatment for hepatic malignant solid tumors in irreversible electroporation field.
  • 2020year
    • Steep Pulse Therapeutic Apparatus was approved by China’s Innovative Medical Device Special Approval.
    • Shanghai Yuanshan Medical Technology Co.,Ltd was founded officially.
  • 2019year
    Steep Pulse Therapeutic Apparatus completed clinical trial successfully.
  • 2018year
    • Steep Pulse Therapeutic Apparatus started human clinical trial.
    • The second product-Pulsed Field Ablation Therapeutic Apparatus(For atrial fibrillation treatment) was initiated officially.
  • 2016year
    The first product-High Voltage Steep Pulse Therapeutic Apparatus (also known as NanoKnife), completed prototype development.
  • 2014year
    Tianjin Intelligent Health Co.,Ltd was founded officially.
  • 2013year
    Technical team established and initiate the research project on irreversible electroporation (IRE) technology.
  • R&D Team
    A team consists of professors, associate professors + doctoral and master students who have devoted themselves to technology development for over 30 years.
  • Technical Introduction
    Irreversible electroporation technology creates irreversible nano-sized structural pores on the surface of cell membranes by applying high-voltage and low-energy direct current pulses,making cell homeostasis unbalanced leading to apoptosis.The technology has gain high significance for its unique advantages such as non-thermal ablation and no damage to blood vessels and nerve structures in global tumor treatment and atrial fibrillation treatment field.
  • Intellectual Property
    Alpmed owns independent intellectual property rights and all key technologies have obtained national patents with a total of nearly 50 patents. ALpmed has now become the leading technology pioneer in the field of irreversible electric perforation in China.
  • Product Layout
    Currently,Alpmed has successfully established two major product directions in malignant tumors treatment and cardiovascular diseases treatment.Steep Pulse Therapeutic Apparatus has obtained the first registration certificate for medical device(Class III) for hepatic malignant tumors in irreversible electroporation field.Pulsed Field Ablation Therapeutic Apparatus targeted at cardiac electrophysiology therapy has obtained authorization of patent for an invention and started multicenter clinical trial in over 10 hospitals nationwide.In February 2022, It was approved as the first domestically produced PFA product by China’s Innovative Medical Device Special Approval.